Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications.
Immunogen:
Synthesized peptide derived from Thrombopoietin receptor at AA range: 321-370
Storage:
Rabbit
Storage:
-20°C/1 year
Clonality:
Polyclonal
Isotype:
IgG
Concentration:
1 mg/ml
Observed Band:
69,40kD
GeneID（Human）:
4352
Human Swiss-Prot No:
P40238
Cellular localization:
Cell membrane ; Single-pass type I membrane protein. Golgi apparatus . Cell surface .
Background:
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important
Western Blot analysis of MCF7 cells using CD110 Polyclonal Antibody. Secondary antibody(catalog#:RS0002) was diluted at 1:20000
Immunohistochemical analysis of paraffin-embedded human-liver, antibody was diluted at 1:100
Immunohistochemical analysis of paraffin-embedded human-liver, antibody was diluted at 1:100